S&P 500   3,362.03 (-0.54%)
DOW   29,185.16 (-0.72%)
QQQ   234.00 (-0.27%)
AAPL   317.44 (-2.31%)
FB   217.31 (+1.46%)
MSFT   186.78 (+0.77%)
GOOGL   1,520.84 (+0.14%)
AMZN   2,139.41 (+0.21%)
CGC   22.21 (+0.36%)
NVDA   291.91 (+0.73%)
BABA   218.41 (-0.56%)
MU   57.72 (-1.33%)
GE   12.82 (-0.16%)
TSLA   843.01 (+5.37%)
AMD   56.44 (+2.04%)
T   38.16 (-0.24%)
ACB   1.59 (+0.63%)
NFLX   387.40 (+1.84%)
PRI   135.27 (-1.15%)
BAC   34.24 (-1.75%)
DIS   138.39 (-0.82%)
GILD   67.18 (-0.56%)
S&P 500   3,362.03 (-0.54%)
DOW   29,185.16 (-0.72%)
QQQ   234.00 (-0.27%)
AAPL   317.44 (-2.31%)
FB   217.31 (+1.46%)
MSFT   186.78 (+0.77%)
GOOGL   1,520.84 (+0.14%)
AMZN   2,139.41 (+0.21%)
CGC   22.21 (+0.36%)
NVDA   291.91 (+0.73%)
BABA   218.41 (-0.56%)
MU   57.72 (-1.33%)
GE   12.82 (-0.16%)
TSLA   843.01 (+5.37%)
AMD   56.44 (+2.04%)
T   38.16 (-0.24%)
ACB   1.59 (+0.63%)
NFLX   387.40 (+1.84%)
PRI   135.27 (-1.15%)
BAC   34.24 (-1.75%)
DIS   138.39 (-0.82%)
GILD   67.18 (-0.56%)
S&P 500   3,362.03 (-0.54%)
DOW   29,185.16 (-0.72%)
QQQ   234.00 (-0.27%)
AAPL   317.44 (-2.31%)
FB   217.31 (+1.46%)
MSFT   186.78 (+0.77%)
GOOGL   1,520.84 (+0.14%)
AMZN   2,139.41 (+0.21%)
CGC   22.21 (+0.36%)
NVDA   291.91 (+0.73%)
BABA   218.41 (-0.56%)
MU   57.72 (-1.33%)
GE   12.82 (-0.16%)
TSLA   843.01 (+5.37%)
AMD   56.44 (+2.04%)
T   38.16 (-0.24%)
ACB   1.59 (+0.63%)
NFLX   387.40 (+1.84%)
PRI   135.27 (-1.15%)
BAC   34.24 (-1.75%)
DIS   138.39 (-0.82%)
GILD   67.18 (-0.56%)
S&P 500   3,362.03 (-0.54%)
DOW   29,185.16 (-0.72%)
QQQ   234.00 (-0.27%)
AAPL   317.44 (-2.31%)
FB   217.31 (+1.46%)
MSFT   186.78 (+0.77%)
GOOGL   1,520.84 (+0.14%)
AMZN   2,139.41 (+0.21%)
CGC   22.21 (+0.36%)
NVDA   291.91 (+0.73%)
BABA   218.41 (-0.56%)
MU   57.72 (-1.33%)
GE   12.82 (-0.16%)
TSLA   843.01 (+5.37%)
AMD   56.44 (+2.04%)
T   38.16 (-0.24%)
ACB   1.59 (+0.63%)
NFLX   387.40 (+1.84%)
PRI   135.27 (-1.15%)
BAC   34.24 (-1.75%)
DIS   138.39 (-0.82%)
GILD   67.18 (-0.56%)
Log in

NASDAQ:BRLI - Bio-Reference Laboratories Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Bio-Reference Laboratories, Inc is a clinical testing laboratory, which offers testing, information and related services to physician offices, clinics, hospitals, employers and governmental units. The Company offers a range of laboratory testing services utilized by healthcare providers in the detection, diagnosis, evaluation, monitoring and treatment of diseases. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryHealth Care Services
SectorN/A
Current SymbolNASDAQ:BRLI
CUSIP09057G60
Phone+1-201-7912186

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive BRLI News and Ratings via Email

Sign-up to receive the latest news and ratings for BRLI and its competitors with MarketBeat's FREE daily newsletter.


Bio-Reference Laboratories (NASDAQ:BRLI) Frequently Asked Questions

What is Bio-Reference Laboratories' stock symbol?

Bio-Reference Laboratories trades on the NASDAQ under the ticker symbol "BRLI."

How were Bio-Reference Laboratories' earnings last quarter?

Bio-Reference Laboratories Inc (NASDAQ:BRLI) issued its quarterly earnings data on Thursday, December, 18th. The medical research company reported $0.66 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.63 by $0.03. The medical research company earned $227.60 million during the quarter, compared to analyst estimates of $228.81 million. The business's quarterly revenue was up 18.4% compared to the same quarter last year. During the same period last year, the firm earned $0.40 EPS. View Bio-Reference Laboratories' Earnings History.

Has Bio-Reference Laboratories been receiving favorable news coverage?

Press coverage about BRLI stock has trended extremely negative this week, according to InfoTrie Sentiment. The research firm scores the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Bio-Reference Laboratories earned a news sentiment score of -5.0 on InfoTrie's scale. They also assigned media stories about the medical research company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Bio-Reference Laboratories.

Who are some of Bio-Reference Laboratories' key competitors?

What other stocks do shareholders of Bio-Reference Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Reference Laboratories investors own include Opko Health (OPK), Anacor Pharmaceuticals (ANAC), Gentex (GNTX), Halozyme Therapeutics (HALO), Nektar Therapeutics (NKTR), Rackspace Hosting (RAX), ACADIA Pharmaceuticals (ACAD), Agios Pharmaceuticals (AGIO), Alnylam Pharmaceuticals (ALNY) and Ambarella (AMBA).

What is Bio-Reference Laboratories' official website?

The official website for Bio-Reference Laboratories is http://www.bioreference.com/.

How can I contact Bio-Reference Laboratories?

Bio-Reference Laboratories' mailing address is 481 Edward H Ross Dr, ELMWOOD PARK, NJ 07407-3118, United States. The medical research company can be reached via phone at +1-201-7912186.


MarketBeat Community Rating for Bio-Reference Laboratories (NASDAQ BRLI)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  106 (Vote Outperform)
Underperform Votes:  101 (Vote Underperform)
Total Votes:  207
MarketBeat's community ratings are surveys of what our community members think about Bio-Reference Laboratories and other stocks. Vote "Outperform" if you believe BRLI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BRLI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/18/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel